Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Integrin alpha V beta 1

Integrin alpha V beta 1

Brief Information

Name:Integrin alpha-V/beta-1
Target Synonym:
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

IT1-H82W6-ELISA
 Integrin alpha V beta 1 ELISA

Immobilized Fibronectin at 5 μg/mL (100 μL/well) can bind Biotinylated Human ITGAV&ITGB1 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT1-H82W6) with a linear range of 0.039-0.625 μg/mL (QC tested).

IT1-H5213-ELISA
 Integrin alpha V beta 1 ELISA

Immobilized Recombinant Human Fibronectin at 2 μg/mL (100 μL/well) can bind Human ITGAV&ITGB1 Heterodimer Protein, Tag Free&Tag Free (Cat. No. IT1-H5213) with a linear range of 0.002-0.313 μg/mL (QC tested).

Synonym Name

Integrin alpha V beta 1,ITGAV&ITGB1

Background

Integrin alpha-5/beta-1 is a receptor for ibrinogen. Integrin alpha-1/beta-1, alpha-2/beta-1, alpha-6/beta-1 and alpha-7/beta-1 are receptors for lamimin. Integrin alpha-4/beta-1 is a receptor for VCAM1. It recognizes the sequence Q-I-D-S in VCAM1. Integrin alpha-9/beta-1 is a receptor for VCAM1, cytotactin and osteopontin. It recognizes the sequence A-E-I-D-G-I-E-L in cytotactin. Integrin alpha-V/beta-1 is also a receptor for vitronectin. Beta-1 integrins recognize the sequence R-G-D in a wide array of ligands. Isoform 2 interferes with isoform 1 resulting in a dominant negative effect on cell adhesion and migration (in vitro). When associated with alpha-7/beta-1 integrin, regulates cell adhesion and laminin matrix deposition.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
PLN-1474 PLN-1474 Phase 1 Clinical Pliant Therapeutics Inc, Novartis Pharma Ag Non-alcoholic Fatty Liver Disease; Liver Cirrhosis Details
IDL-2965 IDL-2965 Phase 2 Clinical Indalo Therapeutics Inc Non-alcoholic Fatty Liver Disease; Idiopathic Pulmonary Fibrosis Details
Bexotegrast PLN-74809 Phase 2 Clinical Pliant Therapeutics Inc Idiopathic Pulmonary Fibrosis; Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Cholangitis, Sclerosing Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message